RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants
The group, called the Advisory Committee on Immunization Practices, or ACIP, also voted unanimously to include Merck's shot in the government's list of recommended childhood immunizations that receive wide insurance coverage.
The votes in favor of the injectable antibody, Enflonsia, are a sigh of relief for drugmakers and the medical community after Kennedy earlier this month gutted the panel and tapped replacements, some of whom are well-known vaccine critics.
The signoff will allow the company to launch the shot ahead of the RSV season that typically kicks off around fall and winter and lasts through the spring. Enflonsia, recommended for infants during their first RSV season, will compete head-to-head with a rival shot from Sanofi and AstraZeneca called Beyfortus.
Both are preventative monoclonal antibodies, which deliver antibodies directly into the bloodstream to provide immediate protection. But each targets a different part of the virus, making it difficult to compare them directly.
RSV causes thousands of deaths among older Americans and hundreds of deaths among infants each year, and complications from the virus are the leading cause of hospitalization among newborns. In a mid- to late-stage trial on Enflonsia, the shot reduced RSV-related hospitalizations by more than 84% and decreased hospitalizations due to lower respiratory infections by 90% compared with a placebo among infants through five months.
Two of the vaccine critics on the panel, Retsef Levi and Vicky Pebsworth, voted against recommending Merck's shot and questioned its safety throughout the meeting.
But some other members underscored the safety of Merck's shot, which won approval from the Food and Drug Administration earlier this month.
"These are truly remarkable products. They are safe and they're effective, and I don't think there's any further data that needs to be presented," said member Dr. Cody Meissner, a professor of pediatrics at the Geisel School of Medicine at Dartmouth.
The ACIP "work group has spent an enormous amount of time, the FDA has spent an enormous amount of effort looking at safety and efficacy, and it is simply not an issue here," said Meissner, who has also held advisory roles at the CDC and FDA.
Other experts at the meeting, who aren't members of the committee, agreed.
"This is a tremendous advance for medical science, and I urge the committee to approve and pass this resolution so that we can continue to protect our children and keep them healthy," said Dr. Jason Goldman, president of the American College of Physicians.
Levi said he voted against the shot because he believes it is not "ready to be administered to all healthy babies. He added, "I think we should take a more precautionary approach to this."
The vote specifically recommends one dose of Merck's shot for infants ages 8 months or younger born during or entering their first RSV season.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
6 hours ago
- Business Insider
Ultragenyx receives CRL from FDA for UX111 gene therapy
Ultragenyx (RARE) Pharmaceutical announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for its Biologics License Application for UX111 AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A. 'Our goal is to get UX111 to patients as quickly as possible knowing how critical this first therapy is to the Sanfilippo community. We have been diligently responding to the recent CMC observations and our priority is to resolve them so that we can resubmit the BLA as soon as possible,' said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. 'We believe the CMC observations are readily addressable and many have already been addressed. While the CRL will delay the potential approval of UX111 to 2026, we are working with urgency to respond and resubmit.' In the CRL, the FDA requested that the company provide additional information and improvements related to specific aspects of CMC and observations from the recently completed manufacturing facility inspections. The company believes that these observations are readily addressable, related to facilities and processes, and are not directly related to the quality of the product. The company will be working with the FDA over the next few months to resolve the observations. Once resolution is achieved, the company expects to resubmit the BLA and anticipates up to a 6-month review period to follow the resubmission. Clinical review had been ongoing and the FDA has acknowledged that the neurodevelopmental outcome data provided to date are robust and the biomarker data provide additional supportive evidence. The CRL did not note any review issues related to the clinical data package nor clinical inspections, and asked that updated clinical data from current patients be included in the resubmission.
Yahoo
6 hours ago
- Yahoo
FDA approves shot that protects dogs from fleas and ticks for 8-12 months
The U.S. Food and Drug Administration has approved a new shot that protects dogs six months or older against fleas and ticks. Merck Animal Health's Bravecto Quantum is officially the first FDA approved drug that protects dogs from fleas and ticks for eight months to a year, the agency announced on Thursday, July 10. Licensed veterinarians may now administer the parasiticide injection, monitor for adverse reactions and determine the appropriate treatment interval based on each dog, according to the FDA, which prohibits anyone without proper licensing and professional expertise to perform the shots. Christine Royal, Director of Merck Animal Health's Veterinary Professional Services, said the FDA approval sets a new standard offering dog owners a safe and effective option for flea and tick protection. "We take great pride in our company's leadership in long-acting preventative parasiticides and are excited to offer a convenient option that gives dogs year-round comprehensive protection from fleas and ticks in one easy injection they can receive from their veterinarian," Royal said in a news release. Bravecto Quantum is an injectable medication for dogs six months or older that can protect against fleas and ticks for eight to 12 months. The drug uses a unique type of fluralaner that can maintain effectiveness for up to a year, according to Merck Animal Health. The research company encourages dog owners to check with a veterinarian to stop fleas and ticks, which can pose health risks to both animal and human health as some transmit diseases. Fleas, which can live in both warm and cold climates, also cause severe allergic dermatitis in dogs and cats, Merck Animal Health warns. Bravecto Quantum is expected to be available at veterinary clinics and hospitals across the U.S. as soon as August 2025, Merck Animal Health announced. The drug was first approve in Australia and New Zealand in 2023. Last year the European Union followed suit and now its approved in more than 50 nations globally. The FDA is urging pet owners to ask a veterinarian is a safe and effective option for their dogs. Bravecto Quantum contains the ingredient fluralaner, which falls under the antiparasitic drug class known as isoxazolines. The FDA states that while isoxazolines have proven to treat and control fleas and certain ticks in pets, their effectively typically lasts for one month. The FDA also warns that some isoxazoline products have been associated with neurologic adverse reactions in dogs and cats such as muscle tremors, ataxia and seizures. Halfway through 2025, emergency room visits prompted by tick bites peaked to the highest rate in five years nationwide, according to new Centers for Disease Control and Prevention (CDC) data. In the Northeast tick bites accounted for 283 ER visits per 100,000 during the peak month of May, up from 209 around the same time last year, the CDC's Tick Bite Data Tracker shows. By July 6, the CDC reported that emergency department visits for tick bites already surpassed nearly a decade of July records, with 92 visits per 100,000 reported nationwide. The most common ER visitors included children ages 0 to 9 and people over the age of 70. Contributing: Mary Walrath-Holdridge, USA TODAY This article originally appeared on USA TODAY: FDA approves shot that protects dogs from fleas, ticks for 8-12 months
USA Today
6 hours ago
- USA Today
FDA approves shot that protects dogs from fleas and ticks for 8-12 months
The U.S. Food and Drug Administration has approved a new shot that protects dogs six months or older against fleas and ticks. Merck Animal Health's Bravecto Quantum is officially the first FDA approved drug that protects dogs from fleas and ticks for eight months to a year, the agency announced on Thursday, July 10. Licensed veterinarians may now administer the parasiticide injection, monitor for adverse reactions and determine the appropriate treatment interval based on each dog, according to the FDA, which prohibits anyone without proper licensing and professional expertise to perform the shots. Christine Royal, Director of Merck Animal Health's Veterinary Professional Services, said the FDA approval sets a new standard offering dog owners a safe and effective option for flea and tick protection. "We take great pride in our company's leadership in long-acting preventative parasiticides and are excited to offer a convenient option that gives dogs year-round comprehensive protection from fleas and ticks in one easy injection they can receive from their veterinarian," Royal said in a news release. What is Bravecto Quantum? Bravecto Quantum is an injectable medication for dogs six months or older that can protect against fleas and ticks for eight to 12 months. The drug uses a unique type of fluralaner that can maintain effectiveness for up to a year, according to Merck Animal Health. The research company encourages dog owners to check with a veterinarian to stop fleas and ticks, which can pose health risks to both animal and human health as some transmit diseases. Fleas, which can live in both warm and cold climates, also cause severe allergic dermatitis in dogs and cats, Merck Animal Health warns. When will Bravecto Quantum be available? Bravecto Quantum is expected to be available at veterinary clinics and hospitals across the U.S. as soon as August 2025, Merck Animal Health announced. The drug was first approve in Australia and New Zealand in 2023. Last year the European Union followed suit and now its approved in more than 50 nations globally. FDA urges dog owners to check with veterinarian first The FDA is urging pet owners to ask a veterinarian is a safe and effective option for their dogs. Bravecto Quantum contains the ingredient fluralaner, which falls under the antiparasitic drug class known as isoxazolines. The FDA states that while isoxazolines have proven to treat and control fleas and certain ticks in pets, their effectively typically lasts for one month. The FDA also warns that some isoxazoline products have been associated with neurologic adverse reactions in dogs and cats such as muscle tremors, ataxia and seizures. More human ER visits caused by ER visits then years past Halfway through 2025, emergency room visits prompted by tick bites peaked to the highest rate in five years nationwide, according to new Centers for Disease Control and Prevention (CDC) data. In the Northeast tick bites accounted for 283 ER visits per 100,000 during the peak month of May, up from 209 around the same time last year, the CDC's Tick Bite Data Tracker shows. By July 6, the CDC reported that emergency department visits for tick bites already surpassed nearly a decade of July records, with 92 visits per 100,000 reported nationwide. The most common ER visitors included children ages 0 to 9 and people over the age of 70. Contributing: Mary Walrath-Holdridge, USA TODAY
